Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
 

T-Cell Lymphoma Clinical Trials

A listing of T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (121) clinical trials

This clinical trial is provided by Antidote. If approved, the study drug could help patients treat Cutaneous T cell Lymphoma (Mycosis Fungoides)

Phase

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 1 year from the date of signed informed consent (enrollment) until end of study. Continuation in the ...

Phase N/A

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II Stage III or Stage IV T-Cell Non-Hodgkin's Lymphoma

OBJECTIVES: Primary - Establish the safety and dose-limiting toxicities of alemtuzumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) chemotherapy in patients with newly diagnosed, stage II-IV aggressive peripheral T-cell non-Hodgkin's lymphoma. - Measure the pharmacokinetics of alemtuzumab using different subcutaneous doses and schedules to determine the dose ...

Phase

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large veins in the neck or chest). Also before treatment can begin, we will test the subject's blood for viruses which ...

Phase

T Cell Repertoire Analysis of Immune Mediated Skin Diseases

The aim of the study is to characterized the T cell repertoire of individuals with immune mediated skin disease (e.g. psoriasis and mycosis fungoides). Peripheral blood with be collected from volunteers with psoriasis, mycosis fungoides and age matched controls. Fifteen tablespoons of blood will be collected prior to the initiation ...

Phase N/A

Topical Romidepsin in Treating Patients With Stage I or Stage II Cutaneous T-Cell Non-Hodgkin's Lymphoma

OBJECTIVES: Primary - Determine the maximum tolerated dose of topical romidepsin when escalated by concentration, frequency, and body surface area in patients with stage IA, IB, or IIA cutaneous T-cell non-Hodgkin's lymphoma. - To monitor the skin and systemic toxicity of this drug in these patients. Secondary - Determine histone ...

Phase

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I Stage II Stage III or Stage IV Peripheral T-Cell Lymphoma

OBJECTIVES: Primary - To determine the feasibility of adding alemtuzumab to standard cyclophosphamide, doxorubicin hydrochloride, vincristine, and oral prednisolone (CHOP) chemotherapy in patients with stage I-IV peripheral T-cell lymphoma (PTCL). - To assess the side effect profile and early and late toxicities of this regimen in a standard dose-escalation design, ...

Phase

Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma

Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP.The investigators did this trial to evaluate the efficacy and tolerability of the combination chemotherapy of DICE in the patients with NK/T cell lymphoma.

Phase

A Study Of Oral PF-02341066 A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor In Patients With Advanced Cancer

PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine ...

Phase

T-Lymphocytes in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

OBJECTIVES: Primary - To evaluate the safety of autologous T-lymphocytes genetically modified to express artificial T-cell receptors (CAR) targeting the CD19 molecule (CD19CAR) in patients with refractory or relapsed low-grade B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. Secondary - To measure the survival and function of CD19CAR T-cells in vivo. ...

Phase